tirzepatide for addiction Ozempic, Mounjaro may help with alcohol and opioid addiction, study finds : Shots GLP-1 drugs may fight addiction

This will also take into consideration whether youve had side effects or not

Tirzepatide, a dual GIP/GLP-1 agonist, shows numerically higher response rates in trialsapproximately 85% achieve 5% or greater weight losspartly because it targets two appetite pathways instead of one

Same dose, different concentration

doi:10.1016/j.cmet.2022.07.013 Source for half-life approximately 6 days, once-weekly dosing pharmacokinetic rationale, and approximately 95% subcutaneous bioavailability

These medications offer cardiovascular and renal protective effects that may benefit post-bariatric patients with residual metabolic risk factors

Rather than stopping tirzepatide completely, many patients benefit from continuing at a lower maintenance dose or switching to a lower-cost alternative like compounded semaglutide, which activates GLP-1 alone and may cost less while still providing meaningful appetite control